HGS ($HGSI) making Benlysta 24/7 in prep for launch

Human Genome Sciences ($HGSI) has been steadily ramping up its manufacturing ops for Benlysta this year. And now that it's breezed past its expert panel review with a big vote in the lupus drug's favor, HGS says that it's working around the clock to produce more in anticipation of an approval. The FDA has a December 9 deadline for making a decision on the drug, but nothing is guaranteed and some analysts have speculated that questions about labeling could force the agency to take more time before it offers a green light on HGS's first market launch. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.